Re-Check

Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhibitor therapy followed by 2 cycles of platinum-based chemotherapy

II

interventionell

National

Durvalumab, Tremelimumab

Status: In Vorbereitung

Zeitraum

2022

2024

Zentren

25

Zentren gesucht

Patienten

196

11.04.2022

Klinische Settings

IV

2nd line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

AIO-Studien-gGmbH

Förderer

AstraZeneca

Identifier

AIO-TRK-0221

AIO-TRK-0221

2017-003780-35

Kontakt

Leitung

PD Dr. med. Niels Reinmuth

Ansprechpartner*in

Sophie Worthmann
Telefon +49 30 814534461
E-Mail ReCheck@aio-studien-ggmbh.de